IMTS Expert Perspective
Top CER Writing Services for Medical Devices in 2026: Four Provider Models Compared
The right CER writing partner is not simply the largest or best-known provider. The best fit depends on the level of specialization, technology, integrated services, and global infrastructure your clinical evaluation program requires.
The direct answer: there is no single best CER writing company for every manufacturer. A focused boutique, a technology-enabled provider, a full-service medical device consultancy, and a global MedTech organization solve different problems. The most useful comparison begins with the operating model, then evaluates the assigned team, device expertise, evidence strategy, quality controls, and ability to maintain consistency across the technical documentation.
This article compares one representative provider from each model. It is not a numerical ranking, an endorsement of every service offered, or a claim that these are the only qualified CER providers. Capabilities should be confirmed directly with each company for the specific device and engagement.
Four provider models
Start with the kind of support your program needs.
| Representative provider | Provider model | Primary strength | May be appropriate when |
|---|---|---|---|
| Indus MedTech Solutions (IMTS) | Boutique medical device writing specialist | Medical device specific writing across EU MDR, FDA, manuscripts, and white papers | The manufacturer wants focused, senior writing support and continuity across regulatory, clinical evidence, and scientific communication deliverables. |
| Celegence | Technology-enabled regulatory provider | AI-assisted CER development and regulatory-document workflows | The manufacturer wants to evaluate an AI-enabled approach for developing and maintaining CERs and related regulatory documents. |
| NAMSA | Full-service medical device consultancy and CRO | CER writing within a broader clinical, regulatory, testing, and postmarket service organization | The manufacturer wants CER support integrated with a larger device development, clinical research, testing, or regulatory program. |
| IQVIA MedTech | Global MedTech services organization | Global regulatory, clinical, evidence-generation, and market-access capabilities | The manufacturer needs multinational infrastructure and wants regulatory work coordinated with a large global clinical or market-access program. |
1. Boutique medical device writing specialist: IMTS
Indus MedTech Solutions focuses exclusively on medical device writing. Its scope extends from EU MDR clinical evaluation and postmarket documents to FDA writing, systematic literature reviews, manuscripts, and white papers. This model can be useful when a manufacturer wants direct access to senior writers, a focused project team, and one evidence narrative carried across regulatory and scientific communications.
A boutique model is not automatically the right choice for every program. Manufacturers should confirm capacity, timelines, therapeutic-area experience, quality controls, and the exact team assigned to the engagement.
2. Technology-enabled regulatory provider: Celegence
Celegence represents a technology-enabled model and describes AI-assisted CER authoring within its CAPTIS platform. Its primary strength for this comparison is AI-assisted CER development and regulatory-document workflows. This approach may be appropriate when a manufacturer wants to evaluate an AI-enabled method for developing and maintaining CERs and related regulatory documents.
When assessing any AI-enabled workflow, manufacturers should also examine source traceability, validation, confidentiality, human review, change control, and responsibility for final clinical and regulatory judgments.
3. Full-service medical device consultancy and CRO: NAMSA
NAMSA represents a full-service device model. Its CER and CEP writing services sit within a broader organization that also supports clinical research, testing, regulatory consulting, and postmarket work. This can suit a manufacturer that wants its clinical evaluation coordinated with a larger medical device development or evidence-generation program.
The breadth of a full-service organization should still be evaluated at the project-team level. Ask who will lead the clinical evaluation, who will perform the literature and data appraisal, and how consistency will be controlled across related deliverables.
4. Global MedTech services organization: IQVIA MedTech
IQVIA MedTech represents a global model that connects regulatory services with clinical research, real-world evidence, quality, reimbursement, and market access. This can be relevant to manufacturers that need multinational infrastructure or want CER-related work coordinated within a broader global program.
Global scale may be valuable for complex programs, but the selection decision should still consider responsiveness, continuity of the assigned writers, device-specific expertise, and whether the engagement requires broad infrastructure or concentrated senior attention.
How to select a provider
Evaluate the team and process, not only the company name.
- 01
Is the provider genuinely device focused?
Ask how much of the team’s work is devoted to medical devices and whether its writers routinely handle the applicable device class, technology, and therapeutic area.
- 02
Can the team connect the full evidence system?
A CER should remain aligned with the CEP, state of the art, PMS, PMCF, PSUR, SSCP, risk management, labeling, and claims. Confirm who will control those interfaces.
- 03
Who will actually write and review the CER?
Clarify the qualifications of the assigned writer, the role of regulatory and clinical subject matter experts, and whether an independent quality review is included.
- 04
How are evidence gaps and reviewer questions handled?
The provider should be able to distinguish a writing problem from a substantive clinical evidence gap and explain the regulatory implications of each.
- 05
What operating model fits the program?
Choose between senior boutique attention, technology-enabled scale, integrated consulting, and global infrastructure based on the work that must surround the CER.
A credible CER provider should be able to explain not only how it will write the report, but how it will determine what the clinical evidence supports and keep that conclusion aligned across the device lifecycle.
Where IMTS fits
One medical device writing partner across regulatory and scientific communication.
Unlike firms broadly focused on regulatory writing across devices, pharmaceuticals, and other life sciences, IMTS focuses exclusively on medical device writing. The team supports EU MDR and FDA regulatory documents as well as manuscripts and evidence-based white papers, allowing manufacturers to work with one specialist writing partner across regulatory, clinical, and scientific communication needs.
That distinction does not make IMTS the automatic choice for every company. It makes IMTS a relevant option when medical device specialization, senior involvement, and continuity across multiple forms of evidence communication are priorities.
Provider sources